Effects of short- and long-term (-)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain

Brain Research

Volumn 953, Issue 1-2, 2002, Pages 1-11

  Kunikowska, Grazyna ^a   Gallagher, Imelda ^a   Glover, Vivette ^b   Clow, Angela ^c   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

Deprenyl; Glutathione peroxidase; mRNA; Parkinson's disease; Selegiline; Superoxide dismutase

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; SELEGILINE; SODIUM CHLORIDE;

AGE; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; GLOBUS PALLIDUS; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; LONG TERM CARE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; SUBSTANTIA NIGRA;

ANIMALS; BASAL GANGLIA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTATHIONE PEROXIDASE; MALE; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, WISTAR; RNA, MESSENGER; SELEGILINE; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 0037145696     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03187-6     Document Type: Article

References (58)

1. Birkmayer W., Knoll J., Riederer P., Youdim M.B., Hars V., Morton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J. Neural Transm. 64:1985;113-127.
2. Carrillo M.C., Kanai S., Kitani K., Ivy G.O. A high dose of long-term treatment with deprenyl loses its effect on antioxidant enzyme activities as well as on survivals of Fischer-344 rats. Life Sci. 67:2000;2539-2548.
3. Carrillo M.C., Kanai S., Nokubo M., Ivy G.O., Sato Y., Kitani K. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp. Neurol. 116:1992;286-294.
4. Carrillo M.C., Kanai S., Nokubo M., Kitani K. (-)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48:1991;517-521.
5. Carrillo M.C., Kanai S., Sato Y., Ivy G.O., Kitani K. Sequential changes in activities of superoxide dismutase and catalase in brain regions and liver during (-)deprenyl infusion in male rats. Biochem. Pharmacol. 44:1992;2185-2189.
6. Carrillo M.C., Kanai S., Sato Y., Kitani K. Age-related changes in antioxidant enzyme activities are region and organ, as well as sex, selective in the rat. Mech. Ageing Dev. 65:1992;187-198.
7. Carrillo M.C., Kanai S., Sato Y., Nokubo M., Ivy G.O., Kitani K. The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci. 52:1993;925-1935.
8. Carrillo M.C., Kitani K., Kanai S., Sato Y., Ivy G.O. The ability of (-)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective. Life Sci. 50:1992;1985-1992.
9. Carrillo M.C., Kitani K., Kanai S., Sato Y., Miyasaka K., Ivy G.O. The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem. Pharmacol. 20:1994;1333-1338.
10. Castagnoli N., Chiba K., Trevor A.J. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 36:1985;225-230.
11. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
12. Clow A., Hussain T., Glover V., Sandler M., Dexter D.T., Walker M. (-)-Deprenyl can induce soluble superoxide dismutase in rat striata. J. Neural Transm. 86:1991;77-80.
13. Cohen G., Pasik P., Cohen G., Leist A., Mytilineou C., Yahr D. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106:1985;209-210.
14. Elizan T.S., Yahr M.D., Moros D.A., Mendoza M.R., Pang S., Bodian C.A. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Arch. Neurol. 46:1989;1275-1279.
15. Floor E., Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70:1988;268-275.
16. Gallagher I.M., Jenner P., Glover V., Clow A. CuZn-superoxide dismutase transgenic mice: no effect on longevity, locomotor activity and 3H-mazindol and 3H-spiperone binding over 19 months. Neurosci. Lett. 11:2000;221-223.
17. Gallagher I.M., Clow A., Jenner P., Glover V. Long-term effects of pergolide and (-)-deprenyl on 3H-mazindol and 3H-spiperone binding in rat brain. Neurobiol. Aging. 20:1999;709-713.
18. Gerlach M., Youdim M.B.H., Riederer P. Pharmacology of selegiline. Neurology. 47:1996;S137-S145.
19. Greenlund L.J.S., Deckworth T.L., Johnson E.M. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron. 14:1995;303-315.
20. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase B inhibitors. Nature. 311:1984;467-469.
21. Jarvis M.F., Wagner G.C. Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and metamphetamine. Life Sci. 36:1985;249-254.
22. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's Disease. Neurology. 47:1996;S161-S170.
23. Kitani K., Kanai S., Carrillo M.C., Ivy G.O. (-)-Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats. Ann. NY Acad. Sci. 30:1994;60-71.
24. Kitani K., Kanai S., Ivy G.O., Carrillo M.C. Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models. Ann. NY Acad. Sci. 20:1998;291-306.
25. Kitani K., Kanai S., Ivy G.O., Carrillo M.C. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech. Ageing Dev. 111:1999;211-221.
26. Kitani K., Kanai S., Sato Y., Ohta M., Ivy G.O., Carrillo M.C. Chronic treatment of (-)-deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci. 52:1993;281-288.
27. Kitani K., Minami C., Maruyama W., Kanai S., Ivy G.O., Carrillo M.C. Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl. J. Neural Transm. S60:2000;139-156.
28. Kitani K., Miyasaka K., Kanai S., Carrillo M.C., Ivy G.O. Up-regulation of antioxidant enzyme activities by deprenyl. Implications for life span extension. Ann. NY Acad. Sci. 786:1996;391-409.
29. Knoll J. Extension of lifespan of rats by long term (-)deprenyl treatment. Mount Sinai J. Med. 55:1988;67-74.
30. Knoll J. The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol. Scand. S126:1989;83-91.
31. Knoll J. (-)-Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. J. Am. Geriatr. Soc. 40:1992;839-847.
32. Knoll J. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view. Pharmacol. Toxicol. 70:1992;317-321.
33. Knoll J., Dallo J., Yen T.T. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci. 45:1989;525-531.
34. +-treated dopaminergic neurones. Eur. J. Pharmacol. 15:1994;123-124.
35. Kunikowska G., Jenner P. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase. Brain Res. 922:2001;51-64.
36. Kunikowska G., Jenner P. The distribution of copper, zinc- and manganese superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia. Biochem. Pharmacol. 63:2001;1159-1164.
37. Lai C.T., Zuo D.M., Yu P.H. Is brain superoxide dismutase activity increased following chronic treatment with L-deprenyl? J. Neural Transm. S41:1994;221-229.
38. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the UK. Br. Med. J. 311:1995;1602-1607.
39. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311:1984;464-467.
40. Milgram N.W., Racine R.J., Nellis P., Mendonca A., Ivy G.O. Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci. 47:1990;415-420.
41. Myllylä V.V., Sotaniemi K.A., Vourinen J.A., Heinonen E.H. Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 42:1992;339-343.
42. Mytilineou C., Cohen G. Deprenyl protects dopaminergic neurones from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion. J. Neurochem. 45:1985;1951-1953.
43. Mytilineou C., Radcliffe P.M., Leonardi E.K., Werner P., Olanow C.W. L-deprenyl protects mesencephalic dopamine neurones from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68:1997;33-39.
44. Mytilineou C., Radcliffe P.M., Olanow C.W. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurones from excitotoxicity in vitro. J. Neurochem. 68:1997;434-436.
45. Parkinson's Study Group . Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1989;1354-1371.
46. Parkinson's Study Group . Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:1993;176-183.
47. Parkinson's Study Group . Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol. 39:1996;29-36.
48. Parkinson's Study Group . Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol. 39:1996;37-45.
49. Pattichis K., Louca L.L., Clow A., Glover V. Effects of pergolide, (-)-deprenyl and thiordazide on soluble SOD, catalase and glutathione peroxidase in rats striata. Med. Sci. Res. 23:1995;733-735.
50. Paxinos G., Watson C. 2nd Edition The Rat Brain in Stereotaxic Co-ordinates. 1986;Academic Press, San Diego.
51. Rinne J.O., Röyttä M., Pajärvi L., Rummukainen J., Rinne U.K. Selegiline (deprenyl) treatments and death of nigral neurones in Parkinson's disease. Neurology. 41:1991;859-861.
52. Ruehl W.W., Entriken T.L., Muggenburg B.A., Bruyette D.S., Griffith W.C., Hahn F.F. Treatment with L-deprenyl prolongs life in elderly dogs. Life Sci. 61:1997;1037-1044.
53. Semkova I., Wolz P., Schilling M., Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 7:1996;19-30.
54. Tatton W.G., Chalmers-Redman R.M.E. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 47:1996;S171-S183.
55. Tatton W.G., Chalmers-Redman R.M. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann. Neurol. 44:1998;S134-S141.
56. Tatton W.G., Chalmers-Redman R.M., Sud A., Podos S.M., Mittag T.W. Maintaining mitochondrial permeability: an opportunity for new therapy in glaucoma? Surv. Opthalmol. 45:2001;S277-283.
57. Tatton W.G., Greenwood C.E. Rescue of dying neurones: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30:1991;666-677.
58. Thiffault C., Aumont N., Quirion R., Poirier J. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J. Neurochem. 65:1995;2725-2733.